Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Wet Age-Related Macular Degeneration (AMD) market size was valued at USD 9.6 billion in 2024. The market is projected to grow from USD 10.3 billion in 2025 to USD 18.4 billion by 2032, exhibiting a CAGR of 7.8% during the forecast period.
Wet AMD is a chronic eye disorder characterized by abnormal blood vessel growth under the retina, leading to rapid central vision loss. As the advanced form of age-related macular degeneration, it accounts for approximately 10-15% of all AMD cases but is responsible for 90% of severe vision loss associated with the condition. Key treatment approaches include anti-VEGF injections, photodynamic therapy, and laser surgery.
Market growth is primarily driven by the rapidly aging global population, with over 80% of AMD cases occurring in individuals aged 60+. While developed regions currently dominate treatment adoption, emerging economies are seeing accelerated market growth due to improving healthcare infrastructure. Recent therapeutic advances, such as the FDA approval of biosimilars and longer-acting anti-VEGF formulations, are further expanding treatment accessibility and compliance. Major players like Roche (Lucentis), Regeneron (Eylea), and Novartis (Beovu) continue to dominate the market, though emerging therapies targeting complement pathways present future growth opportunities.
Aging Population and Rising Prevalence
The global increase in the aging population is a primary driver for the wet AMD market. Approximately 8.7% of the global population aged 55+ is affected by AMD, with the wet form accounting for 10-15% of cases but causing 90% of severe vision loss. This creates a growing patient pool needing treatment.
Advancements in Anti-VEGF Therapies
Innovations in anti-VEGF treatments like aflibercept and ranibizumab have revolutionized wet AMD management. The market is further propelled by new extended-duration formulations that reduce treatment frequency from monthly to every 12-16 weeks, improving patient compliance.
The global wet AMD treatment market is projected to reach $12.5 billion by 2027, growing at a CAGR of 6.8%.
Increasing healthcare expenditure in developing countries and improving diagnostic capabilities are additional factors driving market expansion.
MARKET CHALLENGES
High Treatment Costs and Accessibility Issues
Anti-VEGF therapies cost approximately $2,000 per injection, creating financial barriers. In developing nations, limited insurance coverage and healthcare infrastructure result in significant undertreatment, with only 30-40% of eligible patients receiving standard care.
Other Challenges
Treatment Burden
Frequent intravitreal injections (6-8 annually) lead to patient fatigue and dropout rates approaching 25% after two years of therapy.
Variable Response Rates
20-30% of patients show suboptimal response to existing anti-VEGF therapies, creating unmet needs for alternative treatments.
Patent Expirations and Biosimilar Competition
The upcoming patent expirations of major anti-VEGF drugs between 2023-2025 will introduce biosimilar competition, potentially reducing brand revenues by 30-40% in affected markets. However, this may improve treatment affordability in price-sensitive regions.
Gene Therapy and Sustained-Duration Treatments
Emerging gene therapies like RGX-314 aim to provide durable VEGF suppression from a single administration. The success of these therapies could capture 15-20% of the wet AMD market within 5 years of approval.
AI-Assisted Diagnostics
Artificial intelligence systems for early AMD detection are achieving 94% accuracy in clinical trials. Widespread adoption could significantly increase treatment-eligible patient identification.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Wet AMD leads the market due to its rapid progression and severe vision loss effects, driving urgent treatment needs and higher therapeutic interventions compared to the slower-progressing Dry AMD variant. The development of advanced anti-VEGF therapies has significantly improved treatment outcomes for Wet AMD patients. |
| By Application |
|
Hospital Treatment dominates the application segment as Wet AMD requires specialized diagnostic equipment and frequent intravitreal injections that are typically administered in hospital settings. The increasing number of ophthalmology departments equipped with advanced retinal imaging systems further strengthens this segment. |
| By End User |
|
Geriatric Population represents the primary end-user segment due to the direct correlation between age and AMD prevalence. The segment's growth is further propelled by increasing life expectancy worldwide and greater awareness about age-related eye disorders among the elderly population. |
| By Treatment Type |
|
Anti-VEGF Therapy maintains market leadership due to its superior efficacy in slowing disease progression and preserving vision. The development of longer-acting VEGF inhibitors and novel drug delivery methods are reinforcing this segment's dominance despite higher treatment costs compared to conventional therapies. |
| By Distribution Channel |
|
Hospital Pharmacies lead distribution channels due to the requirement for professional administration of most Wet AMD treatments and the need for proper storage of biologics. However, online pharmacies are gaining traction for ancillary medications and eye care supplements prescribed alongside primary AMD therapies. |
Global Wet AMD Market Dominated by Ophthalmic Pharmaceutical Giants
The Wet Age-Related Macular Degeneration (AMD) treatment market is primarily dominated by multinational pharmaceutical companies, with Novartis and Regeneron Pharmaceuticals leading through their blockbuster anti-VEGF therapies. These two companies account for over 60% of the global wet AMD treatment market share, with Lucentis (ranibizumab) and Eylea (aflibercept) being their flagship products respectively. Roche, through its subsidiary Genentech, continues to maintain a significant presence through its high-efficacy treatments.
Several biotech firms are emerging as strong competitors with novel approaches to wet AMD treatment. Companies like Adverum Biotechnologies and Neurotech Pharmaceuticals are developing gene therapies and sustained-release drug delivery systems that could transform the treatment paradigm. Asian pharmaceutical firms are also gaining traction through biosimilar versions of major anti-VEGF drugs, particularly in cost-sensitive emerging markets.
List of Key Wet AMD Companies ProfiledNovartis International (Switzerland)
Regeneron Pharmaceuticals (US)
Allergan (Ireland)
GlaxoSmithKline (US)
Gilead Sciences (US)
Neurotech Pharmaceuticals (US)
Ophthotech (US)
Acucela (US)
Adverum Biotechnologies (US)
Kodiak Sciences (US)
The global Wet AMD market, valued at millions in 2024, is projected to reach significant growth by 2031 with a steady CAGR. This expansion is primarily fueled by the rapidly increasing geriatric population worldwide. Clinical studies indicate that Wet AMD affects approximately 10% of individuals over 65 and more than 25% of those over 75 years old, creating substantial treatment demand.
Other TrendsTreatment Accessibility and Patent Expirations
The market has seen increased accessibility to treatments due to off-patent blockbuster drugs entering emerging markets. This development has enabled smaller pharmaceutical companies to compete, particularly in developing nations where cost-effective treatment options are crucial.
Regional Market DynamicsNorth America currently leads in market share due to advanced healthcare infrastructure and high disease awareness, followed by Europe. However, Asia-Pacific is emerging as the fastest-growing region, driven by improving healthcare systems and increasing diagnosis rates in countries like China and India. Market forecasts suggest continued regional diversification in treatment availability and adoption.
Innovation in Treatment Modalities
Recent years have seen significant advancements in anti-VEGF therapies, which remain the gold standard for Wet AMD treatment. Pharmaceutical leaders continue to invest in novel drug delivery systems and combination therapies to improve patient outcomes and treatment adherence.
Competitive Landscape EvolutionThe market remains highly competitive with key players including Novartis, Bayer, and Roche dominating significant shares. Biotech firms are increasingly entering the space with innovative treatment approaches, potentially reshaping the competitive dynamics in coming years.
Regional Analysis: Wet Age-Related Macular Degeneration (AMD) MarketEurope
Europe represents the second-largest Wet AMD market, characterized by diverse reimbursement systems and treatment patterns across countries. Western European nations show high adoption of anti-VEGF therapies, while Eastern European markets face more access limitations. The EMA's approval pathway facilitates timely market entry for new therapies, though price negotiations often delay availability. National healthcare systems influence treatment frequencies and drug preferences. The region sees growing adoption of biosimilars as budget-saving measures, particularly in reference pricing countries. Telemedicine platforms for AMD monitoring are expanding, supported by regulatory frameworks.
Asia-Pacific
The Asia-Pacific region demonstrates the fastest growth potential in Wet AMD treatment, driven by aging populations and improving healthcare access. Japan maintains leadership in the region with its advanced healthcare system and aging demographic. China's market expands rapidly as reimbursement improves for innovative therapies. India and Southeast Asia show growing treatment adoption but face affordability challenges. Regional differences in healthcare infrastructure create disparate treatment patterns. Local pharmaceutical companies are increasingly developing biosimilars and novel therapies tailored to Asian patient populations.
South America
South America's Wet AMD market remains underdeveloped but shows steady growth. Brazil represents the largest market, though economic volatility affects treatment access. Urban centers concentrate specialty care while rural areas face significant treatment gaps. Governments increasingly recognize AMD as public health priority, with some including therapies in public health programs. Economic constraints lead to higher use of laser therapy where available. Private insurers cover innovative treatments for affluent patients in major cities.
Middle East & Africa
The MEA region presents the most varied Wet AMD treatment landscape, with Gulf Cooperation Council countries showing advanced care similar to Western markets. Other Middle Eastern nations and Africa generally have limited treatment access except in private healthcare settings. Wealthier patients often travel internationally for treatment. Diagnostic infrastructure limitations lead to late disease presentation. Some governments are initiating national programs for retinal diseases, but coverage remains limited. Humanitarian initiatives provide treatment access in selected areas.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Wet AMD market was valued at USD 9.6 billion in 2024 and is projected to reach USD 18.4 billion by 2032, exhibiting a CAGR of 7.8%.
Which key companies operate in Global Wet AMD Market?
-> Key players include Roche (Lucentis), Regeneron (Eylea), Novartis (Beovu), Bayer, and Allergan, among others.
-> Key growth drivers include aging global population, increasing prevalence of AMD, and technological advances in anti-VEGF therapies.
-> North America currently dominates the market, while Asia-Pacific is experiencing rapid growth.
-> Emerging treatments include biosimilars, longer-acting anti-VEGF formulations, and therapies targeting complement pathways.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates